NEULAND LABORATORIES Financial Statement Analysis
|
||
The Revenues of NEULAND LABORATORIES have increased by 1.51% YoY .
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 156.23 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
NEULAND LABORATORIES Last 5 Annual Financial Results
[BOM: 524558|NSE : NEULANDLAB]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹951 Cr | ₹937 Cr | ₹763 Cr | ₹667 Cr | ₹527 Cr |
Expenses | ₹808 Cr | ₹790 Cr | ₹661 Cr | ₹608 Cr | ₹477 Cr |
Operating Profit (Excl OI) | ₹143 Cr | ₹147 Cr | ₹102 Cr | ₹58 Cr | ₹50 Cr |
Other Income | ₹2.08 Cr | ₹16 Cr | ₹3.89 Cr | ₹3.49 Cr | ₹4.54 Cr |
Interest | ₹13 Cr | ₹18 Cr | ₹22 Cr | ₹16 Cr | ₹19 Cr |
Depreciation | ₹49 Cr | ₹40 Cr | ₹31 Cr | ₹26 Cr | ₹22 Cr |
Profit Before Tax | ₹82 Cr | ₹105 Cr | ₹53 Cr | ₹20 Cr | ₹14 Cr |
Profit After Tax | ₹64 Cr | ₹81 Cr | ₹16 Cr | ₹16 Cr | ₹12 Cr |
Consolidated Net Profit | ₹64 Cr | ₹81 Cr | ₹16 Cr | ₹16 Cr | ₹12 Cr |
Earnings Per Share (Rs) | ₹127.45 | ₹49.74 | ₹62.85 | ₹12.63 | ₹12.82 |
PAT Margin (%) | 13.73 | 6.71 | 8.61 | 2.13 | 2.47 |
ROE(%) | 17.84 | 7.85 | 10.79 | 2.30 | 3.48 |
ROCE(%) | 20.94 | 9.44 | 12.81 | 7.85 | 3.99 |
Total Debt/Equity(x) | 0.12 | 0.28 | 0.22 | 0.37 | 0.33 |
Key Financials |
||
Market Cap | : | ₹ 9,115.3 Cr |
Revenue (TTM) | : | ₹ 1,580.6 Cr |
Net Profit(TTM) | : | ₹ 317.1 Cr |
EPS (TTM) | : | ₹ 247.7 |
P/E (TTM) | : | 28.7 |
Industry Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | -3.4% | 17.6% | 265.1% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
NEULAND LABORATORIES Revenues
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | 1.51 % |
5 Yr CAGR | 15.88 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹951 Cr | 1.51 | |
Mar2022 | ₹937 Cr | 22.84 | |
Mar2021 | ₹763 Cr | 14.38 | |
Mar2020 | ₹667 Cr | 26.44 | |
Mar2019 | ₹527 Cr | - |
NEULAND LABORATORIES Operating Profit
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -2.86 % |
5 Yr CAGR | 29.68 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹143 Cr | -2.86 | |
Mar2022 | ₹147 Cr | 44.10 | |
Mar2021 | ₹102 Cr | 74.56 | |
Mar2020 | ₹58 Cr | 15.74 | |
Mar2019 | ₹50 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -4.28 % |
5 Yr CAGR | 11.92 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 15% | -4.28 | |
Mar2022 | 15.67% | 17.29 | |
Mar2021 | 13.36% | 52.69 | |
Mar2020 | 8.75% | -8.47 | |
Mar2019 | 9.56% | - |
NEULAND LABORATORIES Profit After Tax
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -20.85 % |
5 Yr CAGR | 51.66 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹64 Cr | -20.85 | |
Mar2022 | ₹81 Cr | 397.38 | |
Mar2021 | ₹16 Cr | -1.40 | |
Mar2020 | ₹16 Cr | 36.30 | |
Mar2019 | ₹12 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 104.62 % |
5 Yr CAGR | 53.55 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 13.73 % | 104.62 | |
Mar2022 | 6.71 % | -22.07 | |
Mar2021 | 8.61 % | 304.23 | |
Mar2020 | 2.13 % | -13.77 | |
Mar2019 | 2.47 % | - |
NEULAND LABORATORIES Earnings Per Share (EPS)
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | 156.23 % |
5 Yr CAGR | 77.57 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹127 | 156.23 | |
Mar2022 | ₹50 | -20.86 | |
Mar2021 | ₹63 | 397.62 | |
Mar2020 | ₹13 | -1.48 | |
Mar2019 | ₹13 | - |
NEULAND LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | 121.82 % |
5 Yr CAGR | 51.36 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 20.94% | 121.82 | |
Mar2022 | 9.44% | -26.31 | |
Mar2021 | 12.81% | 63.18 | |
Mar2020 | 7.85% | 96.74 | |
Mar2019 | 3.99% | - |
NEULAND LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹7,121.3 |
Current MarketCap | : | ₹ 9,115.3 Cr |
Updated EOD on | : | Apr 25,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NEULAND LABORATORIES | -3.4% |
17.6% |
265.1% |
SENSEX | 1.3% |
2.6% |
24% |
NEULAND LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.2% | 12.8% | 65.7% |
S&P BSE MIDSMALLCAP | 2.4% | 10.7% | 64.9% |
S&P BSE ALLCAP | 1.6% | 6% | 40.6% |
S&P BSE HEALTHCARE | -0.2% | 3.7% | 52.1% |
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES Financials
How the annual revenues of NEULAND LABORATORIES have changed ?
The Revenues of NEULAND LABORATORIES have increased by 1.51% YoY .
How the Earnings per Share (EPS) of NEULAND LABORATORIES have changed?
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 156.23 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs